XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q2 2026 | -0.01 | -0.27 | -2600.00% | $1.7M | ❌ Miss | -10.20% | -12.81% | — |
| 2026-02-13 | Q1 2026 | -0.04 | -0.06 | -50.00% | $3.9M | ❌ Miss | +0.00% | -4.92% | -33.94% |
| 2025-12-23 |
| Q4 2025 |
| -0.06 |
| -0.06 |
| +0.00% |
| $0 |
| ➖ Inline |
| — |
| — |
| — |
| 2025-08-12 | Q3 2025 | — | -0.08 | — | $0 | — | -1.18% | +0.59% | +11.83% |
| 2025-02-14 | Q1 2025 | — | -0.09 | — | $0 | — | -5.60% | -6.40% | -52.96% |
| 2024-12-27 | Q4 2024 | — | -0.14 | — | $0 | — | +7.69% | +25.00% | +22.12% |
| 2024-08-12 | Q3 2024 | — | -0.06 | — | $0 | — | +0.00% | -38.75% | -47.19% |
Showing last 7 quarters.